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Abstract: Tea provides health benefits, while oxidation is part of tea processing. The effect of 
oxidation on the antithrombotic properties of tea lipid extracts was evaluated for the first time. Total 
lipids (TL) extracted from fresh tea leaves and commercial tea powder, before and after 30–60 min 
of oxidation, were further fractionated into neutral lipids (NL) and polar lipids (PL). The 
antithrombotic bioactivities of tea TL, PL, and NL were assessed in human platelets against the 
inflammatory mediator platelet-activating factor. PL were further assessed against thrombin, 
collagen, and adenosine diphosphate, while their fatty acid composition was evaluated by GC-MS. 
PL exhibited the strongest antithrombotic effects against all platelet agonists and were rich in 
omega-3 polyunsaturated (ω3 PUFA) and monounsaturated (MUFA) fatty acids. A decline was 
observed in the antithrombotic activities, against all platelet agonists tested, for PL after 60 min of 
oxidation, and on their MUFA content, while their overall ω3 PUFA content and ω6/ω3 ratio 
remained unaffected. A synergistic effect between tea phenolic compounds and PL protects them 
against oxidation, which seems to be the rational for retaining the antithrombotic biofunctionalities 
of PL at a considerable favorable cardioprotective level, even after 60 min of tea oxidation. More 
studies are required to elucidate the mechanisms of the favorable synergism in tea PL extracts. 
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1. Introduction 
Tea is brewed from the dried leaves of the plant Camellia sinensis and is one of the most widely 
consumed beverages in the world. Tea has many health benefits and tea is reported to contain nearly 
4000 bioactive chemical compounds, including polar lipids (PL) and their subclasses of glycolipids, 
phospholipids, essential fatty acids (FA), and polyphenols such as catechins [1–8]. Tea can be mainly 
categorized into three types depending on the level of tea polyphenol oxidation. These include green 
tea (nonoxidized), oolong tea (partially oxidized), and black tea (fully oxidized) [1–3]. All types of tea 
are rich in phenolic compounds such as catechins (i.e., epigallocatechin gallate), flavonols (i.e., 
quercetin), phenolic acids (i.e., caffeic and gallic acids), and methylxanthines, containing 
approximately one-third the amount of caffeine compared with coffee [1–3]. Black tea also contains 
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bioactive derivatives of catechins such as theaflavins and thearubigins, which are favourably formed 
at the expense of catechins during oxidation processing [1–3]. 
The health benefits of tea have previously been associated with putative antioxidant capabilities 
due to their phenolic contents that act against oxidative stress and its related unfavourable 
manifestations [2,3]. However, limited evidence exists that flavonoids can actually inhibit oxidative 
damage in vivo, since phenolic compounds have poor bioavailability and their antioxidant activities 
are affected and altered by their metabolic transformation. Indeed, inhibition of atherosclerosis in 
animal models was not associated with markers of change in oxidative damage by phenolic 
compounds [9]. The favourable effects of tea on several chronic disorders, including cardiovascular 
disease (CVD), seem to have little to do with the antioxidant properties of its phenolic compounds 
against oxidative stress, but more likely to do with other health related mechanisms, including the 
favourable effects of tea on endothelial function, inflammation, and the risk of thrombosis and 
platelet activation [2,3,10–14]. 
The beneficial effects of hot water extracts of tea against platelet aggregation and CVD have been 
studied since the early 1990s [8]. Several tea phenolic compounds have been identified as the active 
components that can inhibit platelet aggregation by affecting arachidonic acid (AA) and its 
eicosanoid-related pathways and through their effects against other platelet agonists and thrombo-
inflammatory mediators, such as the platelet-activating factor (PAF), thrombin, collagen, and 
adenosine diphosphate (ADP) [2,3,10–14]. Tea catechins, isoprenyl gallates, theaflavin, and its galloyl 
esters in black tea extract are potent inhibitors of PAF synthesis and PAF-induced platelet 
aggregation [11,15]. Quercetin and gallic acid are also present in tea and have exhibited antiplatelet 
properties [12,13]. However, many of the observed antiplatelet effects of tea phenolic compounds in 
vitro are due to concentrations that cannot be attained in vivo [12–14], while consumption of large 
quantities of tea polyphenols may cause unwanted side effects [14]. 
Apart from its phenolic content, tea also contains other polar compounds, such as polar lipids 
(PL) (e.g., glycolipids and phospholipids), with several of them being rich in unsaturated FA, 
especially oleic acid (OA) and α-Linolenic acid (ALA), the latter being an essential omega-3 
polyunsaturated FA (ω3 PUFA) [4–8]. OA, ALA, and other ω3 PUFA, such as the docosahexaenoic 
acid (DHA) and the eicosapentaenoic acid (EPA) have also exhibited antiplatelet effects of their own 
[16–19]. However, several PL of natural origin (e.g., from plants, animals, marine sources, 
microorganisms, food byproducts, etc.) and especially those bearing unsaturated FA possess much 
more potent antithrombotic properties against platelet aggregation and thus an overall protective 
effect against several chronic disorders including CVD [8,15,20–29]. 
Tea phenolic compounds along with tea PL and FA (e.g., OA and ALA) have also been found to 
be affected by seasonal variation and several manufacturing processes [1,4–8,30,31]. To our 
knowledge, both the antithrombotic activities of tea PL and the effect of oxidation on the 
biofunctionality and FA composition of tea PL compounds has not been reported to date. Therefore, 
the aim of this study was to evaluate the effects of oxidation levels on the biological activities of tea 
leaf lipids and PL for the first time. The antithrombotic properties of the tea lipids were assessed in 
human platelets against PAF, thrombin, ADP, and collagen. In addition, the changes on the FA 
composition of tea PL was also evaluated, in order to elucidate the effect of each level of oxidation on 
the structure activity relationships of tea derived bioactive PL. 
2. Materials and Methods 
2.1. Materials and Instrumentation 
Analysis of platelet aggregation in human platelet-rich plasma (hPRP) was carried out on a 
Chronolog-490 two channel turbidimetric platelet aggregometer (Havertown, PA, USA), coupled to 
the accompanying AGGRO/LINK software package. 20G safety needles and evacuated sodium 
citrate S-monovettes for blood sampling were purchased from Sarstedt Ltd. (Wexford, Ireland). 
Platelet aggregation related consumables were purchased from Labmedics LLP (Abingdon on 
Thames, UK). Standard PAF, thrombin, BSA, and ginkgolide B were purchased from Sigma-Aldrich 
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(Wicklow, Ireland), while collagen and ADP from Chronolog (Havertown, PA, USA) and aspirin 
(Bayer, Berlin, Germany) was purchased from a pharmacy (Bayer, Berlin, Germany). 1- hexadecyl-2-
docosahexaenoyl-sn-glycero-3-phosphocholine standard (PCS) was purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). Centrifugations were carried out on an Eppendorf 5702R centrifuge 
(Eppendorf Ltd., Stevenage, UK). Spectrophotometric analysis was carried out on a Shimadzu UV-
1800 spectrophotometer (Kyoto, Japan) using a quartz 1 cm cuvette. All glass and plastic 
consumables, reagents, and solvents were of analytical grade and were purchased from Fisher 
Scientific Ltd. (Dublin, Ireland). 
2.2. Samples of Tea Assessed Before and After Oxidation Processing 
Fresh tea leaves samples were obtained from a specific and widely available clone of the Camellia 
senensis L. plant, commonly known as black tea, withered for 16–18 h at room temperature, flash 
frozen with liquid nitrogen and grinded using a mortar and pestle. The leaves were left to defrost 
before they were exposed to different levels of oxidation, before (T0) and after 30 (T30) and 60 min 
(T60) of oxidation in the dark. Tea leaves were oxidized in an in-house oxidation unit developed for 
lab-scaled R&D tea processing experiments at Queen’s university, Belfast. The oxidation unit 
includes a shelf to hold the samples, a thermostat heating system to control temperature, and fans to 
ensure the flow of oxygen. When temperature stabilized at 32 °C and constant air stream (0.5 L/min), 
grinded tea samples (T30 and T60), were placed on the shelf within the oxidation unit. After 30 and 
60 min, the leaves were removed and immediately placed in an oven at 103 °C to inhibit the oxidation 
reaction by drying. The freshly oxidized tea leaves were removed from the oven when they reached 
a constant weight at 103 °C. Dried leaves were milled to a powder using a ball mill for 5 min at a 
speed of 500 rpm. In addition, tea powder of commercial tea (CT) from a leading tea brand in Ireland 
(Barry’s Tea), was also analyzed as a control sample. 
2.3. Extraction and Isolation of Total, Neutral, and Polar Lipids From Tea Leaves Before (0 min) and After 30 
and 60 min of Oxidation 
Several tea samples of T0, T30, T60, and TC (n = 3 in each case), were homogenized mechanically 
by a Waring blender (Fisher Scientific Ltd., Dublin, Ireland) into a mixture of 
chloroform/methanol/water (1:2:0.8), the homogenized mixtures were filtrated, and their total lipids 
(TL) were extracted, as previously described [24,25], based on the Bligh and Dyer extraction method 
[32]. By the counter-current distribution method of Galanos and Kapoulas [33] all TL extracts were 
further fractionated into their neutral lipids (NL) and PL fractions, as previously described [24,25]. 
2.4. Human Platelet Aggregation Studies Against PAF, Thrombin, Collagen, and ADP of Lipid Extracts 
From Tea Leaves Before (0 min) and After 30 and 60 min of Oxidation 
The evaluation of the antithrombotic properties of lipid extracts from tea leaves before (0 min) 
and after 30 and 60 min of oxidation against aggregation of human platelets induced by the 
inflammatory and thrombotic mediators, PAF and thrombin, and by the well-established platelet 
agonists collagen and ADP were performed in hPRP from healthy donors, as previously described 
[24,25,34]. The Ethics Committee of the University of Limerick approved the protocol, which was 
performed in accordance with the Declaration of Helsinki. Healthy donors were fully aware that their 
blood samples were used in our study and written consent was provided. 
Briefly, the blood samples were collected from each donor by a phlebotomist in sodium citrate 
anticoagulant and were centrifuged at 194× g for 18 min at 24 °C with no brake applied. The 
supernatant hPRP was then transferred to polypropylene tubes at room temperature for the 
aggregation bioassays, whereas platelet-poor plasma (PPP) was obtained by further centrifuging the 
specimens at 1465× g for 20 min at 24 °C with no brake applied. hPRP was adjusted to 500,000 
platelets/µL if required by addition of the respective volume of PPP according to the absorbance of 
the hPRP measured in spectrophotometer. 
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Standard stock solutions of active thrombin, collagen, and ADP dissolved in saline were further 
diluted in saline prior testing. Aspirin was also dissolved in saline prior testing. Aliquots of standard 
PAF stock solution in chloroform/methanol (1:1 v/v) were evaporated under a stream of nitrogen and 
redissolved in BSA (2.5 mg BSA/mL saline) to obtain PAF solutions with final concentrations into 
aggregometer cuvette ranging from 0.26 nM to 0.26 µM. The examined tea TL, NL, and PL samples 
and the standards of ginkgolide B and PCS, were also dissolved in BSA (2.5 mg BSA/mL saline). 
Then, 250 µl of PRP was added to an aggregometer cuvette at 37 °C with stirring at 1000 rpm. 
The PRP was calibrated using the PPP as a blank. The maximum-reversible PAF, thrombin, collagen, 
and ADP-induced platelet aggregation was determined as 100% aggregation, which was also used as 
baseline (0% inhibition) in the absence of any sample, by adding appropriate amounts of each platelet 
agonist in the aggregometer cuvette, in order to reach specific final concentrations; for PAF 
approximately 0.1–1 nM, for thrombin approximately 0.01–0.4 U/mL, for collagen approximately 1–
5 µg/mL, and for ADP approximately 2–10 μΜ. 
Aggregation of hPRP induced by each agonist (PAF, thrombin, collagen, or ADP) was calculated 
first at 0% inhibition of baseline in a cuvette (100% aggregation) in the absence of any sample, whereas 
after the pre-incubation of hPRP with several amounts (µg) of the test samples for 2 min (a different 
cuvette was used for each amount of the sample tested), the same amount of the agonist was added 
and the reduced aggregation was calculated. Thus, a linear curve at the 20%–80% range of the 
percentage of inhibition against PAF, thrombin, collagen, and ADP-induced aggregation of hPRP to 
the concentrations of each sample was deduced. From this curve, the concentration (µg) of the test 
sample that led to 50% of the agonist induced aggregation of hPRP was calculated as the 50% 
inhibitory concentration value also known as the IC50 value (half-maximal inhibitory concentration) 
for each sample. 
The resulting IC50 values were expressed as a mean value of the mass of lipid/standard (µg) in 
the aggregometer cuvette ± standard deviation (SD). All experiments were performed several times 
(n = 6) for each tea lipid sample (n = 6), using a different donors blood sample for each replicate. 
2.5. Gas Chromatography-Mass Spectrometry of Polar Lipids from Tea Leaves Before (0 min) and After 30 
and 60 min of Oxidation 
GC-MS analysis of the FA composition of the PL fractions from each tea sample (T0, T30, and 
T60) was carried out, as previously described [24,25]. 
2.6. Statistical Analysis 
Normality for all IC50 values and FA composition obtained for each lipid sample was tested using 
Kolmogorov–Smirnov criterion. Subsequently, one-way analysis of variance (ANOVA) was used for 
all comparisons of IC50 values against PAF, thrombin, collagen, and ADP platelet aggregation, while 
Kruskal–Wallis nonparametric multiple comparison test was used for comparisons in the FA 
composition acquired from the CG-MS analysis. Differences were considered to be statistically 
significant when the p-value was less than 0.05 (p < 0.05). The data were analyzed using a statistical 
software package (IBM-SPSS statistics 25 for Windows, SPSS Inc., Chicago, IL, USA). 
3. Results and Discussion 
It is now recognized that the favorable effects of tea against several chronic disorders, including 
CVD, have more to do with its favorable effects on endothelial function, inflammation, and risk of 
thrombosis related to platelet activation and aggregation [2,3,10–14]. However, several 
manufacturing processes affect various compounds of tea leaves, such as their phenolic and other 
polar compounds like PL and FA (e.g., OA and ALA) [1,4–8,30,31]. 
In the present study, TL extracted from unoxidized and oxidized tea leaves (T0, T30, and T60) 
and from CT, were further fractionated into NL and PL fractions. Subsequently, their antithrombotic 
activities were assessed for the first time against aggregation of human platelets induced by the most 
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well established platelet agonists and inflammatory mediators, namely PAF, thrombin, collagen, and 
ADP. 
The obtained amounts of TL, PL, and NL (expressed as g of lipids per 100 g of tea sample) for 
all tea samples (T0, T30, T60, and CT) are given in Table 1. In these tea samples the main lipid 
components were found to be polar compounds, while the neutral lipids were found to be a minor 
component (Table 1). 
Table 1. Yield of extraction of lipid content (TL, PL, and NL) of the tea samples before (0 min) and 
after 30 and 60 min of oxidation in comparison with commercial tea. 
Tea Sample TL * NL * PL * 
CT 8.1 ± 1.5 0.8 ± 0.3 7.3 ± 1.2 
T(0) 9.6 ± 4.9 1.6 ± 0.7 8.0 ± 5.6 
T(30) 9.6 ± 0.6 0.3 ± 0.1 9.3 ± 0.3 
T(60) 10.7 ± 4.0 0.9 ± 2.0 9.8 ± 2.0 
* Expressed as mean values of g of lipids per 100 g of each marine source (mean ± SD, n = 6); TL: Total 
lipids; PL: Polar lipids; NL: Neutral lipids; CT: Commercial tea; T(0): Tea leaf samples before (0 min) 
oxidation; T(30): Tea leaf samples after 30 min of oxidation; T(60): Tea-leaf samples after 60 min of 
oxidation; SD: Standard deviation. 
The yields of PL extracts in all tea samples tested (approximately 7–10 g of PL per 100 g of tea 
sample) were at least two times higher than previously reported ones for tea (approximately 3–5 g of 
PL per 100 g of tea sample) [4,5]. The higher yield of polar compounds observed in all tea samples in 
the present study seem to be related with the different extraction methods employed than those used 
in the previously reported studies for tea polar lipids [4,5]. 
More specifically, in our study we used the well-established Bligh and Dyer extraction method 
for obtaining TL extracts [32], coupled with the efficient counter-current distribution of Galanos and 
Kapoulas [33], as previously described [24]. When this methodology was previously applied to other 
plant sources and related products that are also rich in polyphenols and bioactive polar compounds 
(e.g., red and white wine, musts, grapes, olive oil, sunflower oil, several kind of beers, and brewery 
byproducts), the bioactive phenolic compounds migrated to the PL fraction of the TL extracts within 
these conditions [25–28,35,36]. 
Similarly, the methodology applied in the present study facilitated the recovery of the majority 
of the tea polar compounds within the TL extracts of tea leaves, and from them the separation of the 
PL fractions that are rich in bioactive polar compounds and in which tea polyphenols comigrate. 
Therefore, in comparison with previous studies in tea PL [4,5], the higher amounts of PL extracted 
from the tea leaves in this study took place because of the comigration of phenolic compounds in 
these tea PL fractions due to the experimental extraction conditions applied. This is related to the fact 
that several phenolic compounds have similar to slightly higher polarity than classic PL subclasses 
of glycolipids and phospholipids. A characteristic example of that is the naturally occurring fatty 
esters of catechins in several tea varieties, namely phenolipids, which have a high antioxidant 
capacity and similar polarity and amphiphilic properties with classic PL subclasses, and thus 
comigrate into PL extracts [37,38]. 
The in vitro antithrombotic properties of the TL, NL, and PL extracts from all tea samples, 
against PAF-induced aggregation of human platelets were expressed as IC50 values (Figure 1). The 
lower the IC50 value against PAF for a lipid extract the stronger its antithrombotic properties. 
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Figure 1. The antithrombotic effects of TL (a), PL (b), and NL (c) extracts from tea leaf samples, before 
(0 min) and after 30 and 60 min of oxidation, against PAF-induced aggregation of human platelets, in 
comparison to those of CT. Results are expressed as IC50 (half-maximal inhibitory concentration) 
values that reflect the inhibitory strength of each TL, PL, and NL extract against PAF-induced platelet 
aggregation and is expressed as mean values of µg of lipids in the aggregometer cuvette that causes 
50% of inhibition on PAF-induced aggregation of platelets in hPRP ± SD. * Indicates statistical 
significant differences (p < 0.05). TL: Total lipids; PL: Polar lipids; NL: Neutral lipids; CT: Commercial 
tea samples; PAF: Platelet-activating factor; hPRP: Human platelet-rich plasma; SD: Standard 
deviation. 
In this study, it was found for the first time that from all the lipid extracts tested that were 
derived from tea leaf samples at several stages of oxidation (T0, T30, and T60) and from CT, the PL 
extracts exhibited the strongest antithrombotic activities against PAF-induced aggregation of human 
platelets (Figure 1b). 
It was also found that the TL extracts from all tea samples exhibited a potent anti-PAF effect 
(Figure 1a), which was slightly lower than that of their PL fractions. In contrast, all of the NL fractions 
had much lower anti-PAF effects (Figure 1c). This is also in accordance with previously reported 
outcomes for TL extracts from wine and beer that were also rich in higher amounts of PL, including 
bioactive phenolic and classic PL compounds. The TL also had higher bioactivities in comparison to 
the NL, which were less bioactive and in lower amounts [26,27,36]. 
The FA composition of the PL extracts from all tea samples are shown in Table 2. In all the tea 
PL samples, the PUFA and especially the essential ω3 PUFA ALA (18:3ω3), were the most abundant 
class of FA, followed by lower amounts of saturated fatty acids (SFA) such as the palmitic (16:0) and 
stearic (18:0) acids, and significantly less but considerable amounts of MUFA, such as OA (18:1c9). 
These results are in accordance with previous results for this tea variety [4,6–8,30,31,38], but also for 
other tea varieties [39–41]. 
In addition, in the majority of the tea PL, other MUFA were also present in less but considerable 
amounts, such as the palmitoleic (16:1c9), cis-vaccenic (18:1c11), and gadoleic (20:1c9) acids. 
Considerable amounts of ω6 PUFA were also present, with the most abundant being linoleic acid 
(LA; 18:2ω6), followed by much less but notable amounts of eicosatetraenoic acid (20:4ω6). 
Interestingly, much less but considerable amounts of other long chain (LC) ω3 PUFA, such as 
the EPA (20:5ω3) and the DHA (22:6ω3), were also detected in these tea samples for the first time. It 
has been previously proposed that plant sources do not contain such LC-ω3 PUFA due to lack of 
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appropriate enzyme machinery for producing them from ALA and LA, yet Guil et al. have reported 
the presence of low amounts of both EPA and DHA in several natural plants [41], which is in 
accordance with the results of this study. 
Table 2. The fatty acid profile of the PL extracts from tea leaf samples, before (0 min) and after 30 and 
60 min of oxidation, in comparison to that of CT, expressed as a percentage of the total fatty acids of 
each sample (mean ± SD, n = 3). 
Fatty Acid 0M 30M  60M CT 
14:0 0.700 ± 0.138 a  0.135 ± 0.102 ab 0.122 ± 0.003 b 0.227 ± 0.019 ab 
14:1 ND ND ND 0.064 ± 0.013 
15:0 0.120 ± 0.012 a  0.047 ± 0.002 b ND 0.091 ± 0.003 ab 
16:0 24.60 ± 0.355 ab 19.41 ± 1.117 a 23.38 ± 0.947 ab 28.11 ± 2.014 b 
16:1 c9 1.927 ± 0.033 ab 1.461 ± 0.034 a 1.752 ± 0.073 ab 2.217 ± 0.080 b 
17:0 0.352 ± 0.010 b 0.274 ± 0.017 ab 0.020 ± 0.025 a 0.332 ± 0.022 ab 
18:0 6.408 ± 0.241 ab 8.496 ± 0.173 b 7.930 ± 0.124 ab 6.013 ± 0.099 a 
18:1 c9 9.965 ± 0.149 ab 11.95 ± 0.274 b 8.039 ± 0.114 ab 7.840 ± 0.200 a 
18:1 c11 1.500 ± 0.115 b 1.116 ± 0.048 ab 0.787 ± 0.095 a 1.184 ± 0.043 ab 
18:2 c9, c12 19.48 ± 0.222 a 22.34 ± 0.262 a 22.37 ± 0.247 a 20.38 ± 0.839 a 
18:3 c9, c12, c15 29.78 ± 0.011 ab 30.84 ± 0.529 ab 34.22 ± 0.282 b 27.44 ± 0.942 a 
20:0 0.343 ± 0.064 a  0.442 ± 0.038 a ND 0.209 ± 0.032 a 
20:1 c9  1.105 ± 0.044 b 0.698 ± 0.030 ab ND 0.379 ± 0.051 a 
20:4 c5, c8, c11, c14 0.344 ± 0.0109 ab 0.397 ± 0.018 b ND 0.244 ± 0.033 a 
20:5 c5, c8, c11, c14, 
c17 
0.732 ± 0.016 b 0.655 ± 0.029 ab 0.574 ± 0.050 ab 0.339 ± 0.073 a 
22:0 1.052 ± 0.015 b  ND ND 0.319 ± 0.044 a 
22:5 c7, c10, c13, 
c16, c19 
ND ND ND 0.375 ± 0.050  
22:6 c4, c7, c10, c13, 
c16, c19 
1.390 ± 0.113 b 1.370 ± 0.155 ab 0.518 ± 0.142 a 1.122 ± 0.106 sb 
ω3 31.90 ± 0.215 ab 32.86 ± 0.433 ab 35.56 ± 0.176 b 29.28 ± 1.060 a 
ω6 19.83 ± 0.228 a 22.74 ± 0.271 b 22.37 ± 0.247 ab 20.62 ± 0.860 ab 
ω6/ω3 0.621 ± 0.011 0.692 ± 0.017 0.629 ± 0.010 0.704 ± 0.055 
SFA 32.40 ± 0.532 ab  28.80 ± 0.936 a 31.64 ± 0.829 ab 35.28 ± 1.905 b 
MUFA 15.55 ± 0.141 b 15.28 ± 0.299 ab 10.58 ± 0.051 a 11.90 ± 0.287 ab 
PUFA 51.73 ± 0.413 ab 55.60 ± 0.681 ab 57.68 ± 0.805 b 49.90 ± 1.873 a 
a,b,c Mean values (n = 3), ± standard deviation, with different letters in the same row indicating 
statistical significant differences between the lipid compositions when mean are compared using 
Kruskal–Wallis nonparametric multiple comparison test (p ≤ 0.05). ω6/ω3 ratio uncertainty calculated 
using the following equation: ∆x/x = ([∆ω]6/ω6 + [∆ω]3/ω3) × ω6/ω3. Abbreviations: c: Cis; CT:  
Commercial tea; M: Minutes; MUFA: Monounsaturated fatty acids; PUFA: Polyunsaturated fatty 
acids; SFA: Saturated fatty acids; ND: Nondetectable. 
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PL from several natural sources and foods that are rich in such unsaturated FA, have exhibited 
potent bioavailability, biofunctionality, and antithrombotic properties, not only against PAF [20–29], 
but also against other platelet agonists such as thrombin [23–26,28], collagen, and ADP [25]. 
Therefore, the more potent anti-inflammatory and antithrombotic effects of such PL of natural origin, 
including plant-derived PL, against all these mediators and especially on PAF pathway and 
metabolism, have been translated to an overall favourable protective effect towards several 
inflammation-related disorders. Particularly CVD, in which PAF and these mediators are implicated 
[15,20,22]. The potent anti-PAF effects of the tea PL extracts that were rich in unsaturated FA, were 
of similar potency and efficacy to other anti-PAF PL extracts from natural sources that were also rich 
in ω3 PUFA and OA at their sn-2 position [23–26]. Consequently, the novel results in this study 
concerning the potent antithrombotic bioactivities of the tea PL characterized by their high 
unsaturated FA against PAF further supports the overall favorable health benefits of tea 
consumption. 
Notably, the PL extracts from T0 exhibited significantly stronger anti-PAF effects in human 
platelets, than those of the PL extracts from T60 and CT (p < 0.05 in both comparisons). However, the 
PL extracts from T30 had an intermediate anti-PAF effect (Figure 1b). These results suggest that the 
more time applied in the oxidative process of the tea leaves the lower the bioactivities of their PL 
against PAF-induced human platelet aggregation 
Since tea PL exhibited the most potent anti-PAF effects, in order to fully elucidate the overall 
effects of oxidation we further evaluated for the first time the antithrombotic properties of PL extracts 
from tea leaves at several oxidation levels (T0, T30, and T60) and from CT, against human platelet 
aggregation induced by thrombin, ADP, and collagen. The antithrombotic effects of these tea PL 
extracts against thrombin, collagen, and ADP were also expressed as IC50 values and are shown in 
Figure 2 (2a,b,c for each platelet agonist, respectively). 
It was also found for the first time that PL extracts from all tea samples exhibited potent 
antithrombotic effects against thrombin, collagen, and ADP. Notably, it was also observed that the 
antithrombotic effects of these PL extracts tested against both thrombin and collagen were 
comparable and in the same order of magnitude to their relative biological effects against PAF, while 
their anti-ADP effects were less potent but also in considerable levels. 
Furthermore, in a similar pattern to the results obtained against PAF, it was also found for the 
first time that the PL extracts from T0 had more potent anti-thrombin effects than the PL extracts from 
T60 and CT (p < 0.05 in both comparisons), while the PL extracts from T30 exhibited an intermediate 
anti-thrombin effect (Figure 2a). In the cases of collagen and ADP, the PL extracts from T60 had 
significantly less potent anti-collagen and anti-ADP effects than the PL extracts from all the other tea 
samples (Figure 2b,c) (p < 0.05 in all comparisons for collagen and borderline significance 0.05 < p < 
0.10 in all comparisons for ADP). Again, these results for thrombin, collagen, and ADP, suggest that 
the more the time the oxidative process is applied to the tea leaves the lower the bioactivities of the 
PL against human platelet aggregation induced by these platelet agonists. 
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Figure 2. Antithrombotic effects of PL extracts from tea leaf samples, before (0 min) and after 30 and 
60 min of oxidation, against thrombin (a), collagen (b), and ADP (c) induced aggregation of human 
platelets, in comparison to those of CT. Results are expressed as IC50 (half-maximal inhibitory 
concentration) values that reflect the inhibitory strength of each PL extract against thrombin, collagen, 
and ADP-induced platelet aggregation and is expressed as mean values of µg of PL in the 
aggregometer cuvette that causes 50% of inhibition on thrombin, collagen, and ADP-induced 
aggregation of platelets in hPRP ± SD. * Indicates statistical significant differences (p < 0.05); # indicates 
borderline statistical differences (0.05 < p < 0.10); PL: Polar lipids; CT: Commercial tea samples; ADP: 
Adenosine-5'-diphosphate; hPRP: Human platelet-rich plasma; SD: Standard deviation. 
Nevertheless, the antithrombotic bioactivities of the PL extracts from all these tea samples 
against all platelet agonists (PAF, thrombin, collagen, and ADP) remained in the same order of 
magnitude for each agonist, and thus similar to the IC50 values obtained in human platelets for PL 
from other natural sources against PAF [23–27], thrombin [23–26,28], collagen, and ADP [25]. 
Consequently, although a decline was observed on the antithrombotic activities of the tea PL after 60 
min of oxidation of the tea leaves, yet this reduction was not intense and as a result the antithrombotic 
properties of all tea PL in human platelets against all these platelet agonists were retained at 
substantial levels, comparable to those for PL from other natural sources [23–27]. 
In addition, the PL extracts from T0 exhibited similar anti-PAF bioactivities to their anti-
thrombin and anti-collagen activity, while all these antithrombotic effects were stronger than their 
anti-ADP activity. Instead, the PL extracts from T30 and T60 exhibited significantly stronger anti-PAF 
effects than their anti-thrombin and anti-collagen effects, while all these antithrombotic activities 
were again stronger than their anti-ADP effects for these PL samples too. These results suggest that 
the aforementioned preservation of the antithrombotic activities of tea PL at substantial levels, even 
after 60 min of oxidation of the tea leaves, was more profound in the case of their anti-PAF effects, 
which further implies that the PL compounds with potent anti-PAF bioactivities that are present in 
the tea PL extracts are more sustainable against oxidation. 
In addition, the in vitro antithrombotic properties of aspirin, ginkgolide B (a specific antagonist 
of PAF), and of PCS, a PAF-like molecule bearing ω3 PUFA (DHA) in its structure with both 
antagonistic and agonistic effects against the PAF-pathway were used as controls against aggregation 
of human platelets induced by PAF, thrombin, collagen, and ADP. The IC50 values of each of the 
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controls are shown in Table 3. The platelet aggregation agonistic potency of PAF and of the PAF-like 
PCS molecule are also shown in the same table and are expressed as EC50 values. Again, the lower 
the EC50 value for a platelet agonist the higher its thrombotic potency. 
Both the ginkgolide B and the PAF-like PCS molecule exhibited strong antithrombotic properties 
against all agonists of platelet aggregation, with higher specificity against the PAF-pathway. 
Furthermore, the amounts of the PCS needed for platelet aggregation were at least one order of 
magnitude higher than those needed for inhibiting platelet aggregation, while this agonistic effect on 
human platelets was found to be at least three orders of magnitude lower than that of PAF. Usually, 
acyl-phospholipids bearing ω3 PUFA at their sn-2 glycerol backbone, such as the tested PAF-like 
molecule, either possess a strong inhibitory or a weak agonistic effect or both effects (in different 
concentrations) against the PAF pathways of activating cells (including platelet aggregation). This is 
due to their structural resemblance to the PAF molecule, and thus their antagonistic effect for its 
receptor, but also due to the effect of DHA on the PAF-induced arachidonic acid pathway of 
eicosanoids [20]. Therefore, the dual agonistic and antagonistic effects of the PCS in different 
concentrations, further emphasizes its potent overall inhibitory effect against platelet aggregation 
with a specificity to the PAF-pathway. 
Table 3. Antagonistic and agonistic effects of standards of aspirin, ginkgolide B, and 1-hexadecyl-2-
docosahexaenoyl-sn-glycero-3-phosphocholine (PCS) against PAF, thrombin, collagen, and ADP on 
human platelets (hPRP). 
 Inhibitory Effect * Agonistic Effect 
** 
Standard PAF Thrombin Collagen ADP - 
Aspirin  13.1 ± 5.0 
(291.4 ± 111.8) # 
3.5 ± 1.8 
(77.4 ± 39.3) 
3.0 ± 2.0 
(66.4 ± 52.1) 
3.6 ± 0.8 
(79.6 ± 
18.8) 
ND 
Ginkgolide B 
5.5 ± 4.5 
(65.4 ± 38.9) 
9.2 ± 2.2 
(86.6 ± 21.1) 
12.3 ± 1.8 
(116.0 ± 16.7) ND ND 
PCS 
0.3 ± 0.1 
(1.5 ± 0.3) 
0.6 ± 0.15 
(3.1 ± 0.8) 
0.5 ± 0.04 
(2.3 ± 0.2) 
1.5 ± 0.8 
(7.4 ± 3.8) 17.6 ± 5.6 
PAF - - - - 0.009 ± 0.001 
* Results are expressed as IC50 (half-maximal inhibitory concentration) values that reflect the 
inhibitory strength of each standard against PAF, thrombin, collagen, ADP-induced platelet 
aggregation and is expressed as mean values of µg of standard in the aggregometer cuvette that 
causes 50% of inhibition on thrombin, collagen, and ADP-induced aggregation of platelets in hPRP ± 
SD. # In the parentheses the IC50 values for each standard are also expressed as µM concentration ± 
SD. ** Results are expressed as EC50 (half-maximal effective concentration) values that reflect the 
agonistic strength of each standard to induce aggregation of human platelets and is expressed as mean 
values of µM of standard in the aggregometer cuvette that causes 50% of aggregation of platelets in 
hPRP ± SD. ND: Not detected; SD: Standard deviation; PAF: Platelet activating factor; DHA: 
Docosahexaenoic acid; PC: Phosphatidylcholine. 
It seems that tea PL possess stronger inhibitory effects against the PAF pathway than any 
possible agonistic effect from the constituent lipids in the PL fractions, and in this case, these 
components are acting as mostly PAF inhibitors. This result further emphasizes the high inhibitory 
potency of all tea PL extracts tested in this study that were comparable in the antiplatelet effects to 
several standard inhibitors of platelet aggregation such as aspirin and ginkgolide B. Furthermore, it 
was demonstrated using PCS that the PL themselves were involved in the antiplatelet response, not 
just the phenolic compounds (Table 3). 
Moreover, the GC-MS analysis of the PL extracts from unoxidized (T0) and oxidized (T30 and 
T60) tea leaves revealed that the levels of ALA, their major ω3 PUFA, remained unaffected by this 
oxidation processing (Table 2). These results are in accordance with previously reported studies for 
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this ω3 fatty acid . Therefore, even though a decline was observed in the levels of the lesser ω3 PUFA 
(reduction of EPA levels for both T30 and T60 and of DHA for T60), yet the overall ω3 PUFA content 
remained unaffected after oxidation of the tea leaves. Subsequently, the favorable low levels of the 
ω6/ω3 ratio observed in T0, which were lower than the value of 1/1 for this ratio, were retained in the 
same levels during oxidation (Table 2). These results further support the favourable ω3 PUFA content 
of the tea PL and thus their cardioprotective properties, even after 60 min of oxidation, since it has 
been proposed that low levels for the ω6/ω3 ratio has favorable effects in CVD and other chronic 
disorders [42]. 
At this point it is important to highlight that although the antioxidant tea polyphenols have little 
to do with a proposed in vivo protection against oxidative stress [9], they still play a crucial role as 
primary antioxidants against oxidation of lipids, including PL compounds, in several natural sources, 
foods, beverages, cosmetics, and lipid extracts [37,43,44]. In several leaves and cell membranes, a very 
substantial improvement in oxidative stability, bioavailability, and preservation of the bioactivities 
of both PL and polar phenolic compounds can be achieved by a copresence and synergism of both 
these polar compounds [37,43–47]. Subsequently, the presence of tea phenolic compounds in tea PL 
extracts, seem to facilitate the preservation of the bioactivities of the protected PL compounds. It is 
also possible that the previously reported oxidative stability of conjugative linolenic acids [48], may 
also contribute to the observed in this study preservation of ALA in tea PL after 60 min of oxidation. 
On the other hand, in contrast to the ω3 PUFA, the overall levels of MUFA and those of 
individual OA (18:1c9), palmitoleic (16:1c9), cis-vaccenic (18:1c11), and gadoleic (20:1c9) acids were 
considerably reduced in the PL extracts of tea leaves that were oxidized for 60 min, a result that comes 
in accordance with previous studies in tea [31,49,50]. Especially the observed reduction in their major 
MUFA, OA, seem to be associated with the observed decline in the antithrombotic activities of these 
tea PL extracts against all platelet agonists tested, since OA has favorable antiplatelet effects [18,19]. 
It is also possible that the reduction of the antithrombotic activities of tea PL after 60 min of oxidation 
is related to an oxidation of some of the bioactive tea phenolic compounds that have previously 
reported antiplatelet effects, since they are labile to nonenzymatic oxidation during processing [37]. 
Nevertheless, more studies on the structure activity relationships are required in order to substantiate 
these effects. 
4. Conclusions 
It was found for the first time that tea PL extracts possess strong antithrombotic activities against 
the potent inflammatory mediator PAF, but also against other well-established platelet agonists, 
including thrombin, collagen, and ADP. The antithrombotic properties of tea PL were found to be 
comparable with classic antagonists and inhibitors of platelet aggregation for these agonists, such as 
aspirin, ginkgolide B, and PCS. Furthermore, the tea PL were also found to be rich in ω3 PUFA and 
MUFA, with a favorable ω6/ω3 ratio. However, a reduction of the antithrombotic activities of the tea 
PL extracts was observed after 60 min of oxidation, which was accompanied by a decline in their 
MUFA content. Nevertheless, these reductions were not intense, while the ALA and the overall ω3 
PUFA content and the ω6/ω3 ratio of tea PL remained unaffected. Although the antithrombotic 
properties of all tea PL extracts declined due to oxidation, they remained in the same order of 
magnitude and comparable to those of PL from other natural sources. It is possible that the presence 
of phenolic compounds in these PL extracts may preserve their antithrombotic effects in considerable 
potency and protect them synergistically from the unfavourable effects of oxidation. However, more 
in vitro and in vivo studies are required in order to elucidate the preservation of the favourable effects 
of tea PL extracts due to the co-existing tea phenolic compounds and other bioactive PL subclasses. 
Finally, further studies are required on the putative utilization of highly antithrombotic tea-derived 
PL extracts, either for the fortification of functional foods or for the development of novel food 
supplements. 
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